JO
ALNY icon

John Overdeck’s Alnylam Pharmaceuticals ALNY Stock Holding History

John Overdeck’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-40,700
Closed -$4.78M – 3055
2017
Q3 		$4.78M Buy
40,700
+15,900
+64% +$1.36M 0.02% 829
2017
Q2 		$1.98M Buy
+24,800
New +$1.58M 0.01% 1429
2016
Q4 		– Sell
-12,000
Closed -$813K – 3046
2016
Q3 		$813K Buy
+12,000
New +$847K ﹤0.01% 2117

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

John Overdeck's ALNY Position: Q2 2026 in Review

John Overdeck reduced its Alnylam Pharmaceuticals (ALNY) stake by 5.9% in Q2 2026, selling an estimated $35.2M and leaving 1,875,937 shares worth $565M. The position accounts for 0.41% of the portfolio, ranked #37.

John Overdeck first reported a position in ALNY in Q2 2013 and has held it in 26 quarters since. The position peaked at $659M in Q1 2026. 784 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • John Overdeck held 1,875,937 shares of Alnylam Pharmaceuticals worth $565M as of Q2 2026.
  • John Overdeck sold 116,640 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $35.2M.
  • Alnylam Pharmaceuticals made up 0.41% of John Overdeck's portfolio in Q2 2026, its #37 holding.
  • John Overdeck first reported a position in Alnylam Pharmaceuticals in Q2 2013 and has held it in 26 quarters since.
  • John Overdeck's Alnylam Pharmaceuticals position peaked at $659M in Q1 2026.
  • 784 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.